Kidney Week Disclosures

Total Page:16

File Type:pdf, Size:1020Kb

Kidney Week Disclosures 10/17/2018 ASN Kidney Week 2018 Disclosures 1 Nothing to Full Name Organization Current Employer Consultancy Ownership Interest Research Funding Honoraria Patents and Inventions Scientific Advisor or Membership Speakers Bureau Other Interests/Relationships Disclose Kevin C. Abbott, MD, MPH The National Institutes of Health, NIH (NIDDK) GE NIDDK Tarek Samy Abdelaziz, MBBS, MD Faculty of Medicine-Cairo University Yasser Mohamed Abdelhamid, MD, MBBS Kasr Alainy Hospitals-Cairo University Khaled Abdel-Kader, MD, MS Vanderbilt University Medical Center Vanderbilt University Medical Center Associate editor, BMC nephrology NKF Education committee Emaad M. Abdel-Rahman, MD, PhD, FASN University of Virginia University of Virginia Research with Astra Zeneca Steering Committee KHI : ?Prioritizing $296,000 Symptoms of ESRD Patients for Developing Therapeutic Interventions? Nashila AbdulRahim, DO, MS Carolyn L. Abitbol, MD University of Miami/ Pediatric University of Miami/ Pediatric Vifor Fresenius Medical Care Renal Nephrology Nephrology Pharma France Matthew K. Abramowitz, MD, MS Albert Einstein College of Medicine Albert Einstein College of Medicine Aethlon Medical, Inc. Janssen Pharmaceuticals Wake Forest University School of Glaxo SmithKline Medicine University of Pittsburgh School of Medicine Peter Abt, MD Hospital of the University of Hospital of the University of Merck Associate editor American Journal of Pennsylvania Pennsylvania Transplantation Councilor for the American Society of Transplant Surgeons Essa Abuhelaiqa, MD Abdelrhman Abumoawad, MD Mayo Clinic Mayo Clinic Benjamin A. Adam, MD University of Alberta Alberta Health Services Nancy Day Adams, MD University of Connecticut Health NIH, NIDDK for Loan Forgiveness ASP Council, completing June 30, University of Connecticut School of Center application review, April 2018 2018 Medicine as Professor emeritus Dylan Adamson, MD Mount Sinai Hospital Mount Sinai Hospital Deborah B. Adey, MD University of California, San Francisco University of California, San Francisco Diablo Neurosurgery Medical Group National Kidney Foundation American Society of Transplantation, Board of Managers for the Transplant Nephrology Accreditation Program American society of transplantation- board - councilor at large Lasith Adhikari, PhD University of Florida University of Florida Dwomoa Adu, MD University of Ghana Editorial Board Member, African Board of Trustees, Transplant Links Journal of Nepnrology Committee. UK Maryam Afkarian, MD, PhD University of California, Davis University of California, Davis Marjan Afrouzian, MD University of Texas Medical Branch University of Texas Medical Branch Alexion Pharmaceuticals Farsad Afshinnia, MD, MS, FASN University of Michigan University of Michigan NIDDK K08-DK106523 Behdad Afzali, MD, PhD King's College London King's College London Adhish Agarwal, MD University of Utah University of Utah Keryx August 2015 for 1 meeting Salaries Intermountain Healthcare- worked as Member ASN Chief Department of Medicine, Board member - All India Medical McKayDee Hospital Society of Utah Anil K. Agarwal, MBBS, MD, FASN Ohio State University Ohio State University Akebia Pharmaceuticals- Research ASDIN NKF support NKF ASN CorMedix- Research support Journal of Vascular Access ASDIN GSK The Open Urology and Nephrology RPA St. Jude Medical- Research support Journal Rox Medical- Research support International Journal of Nephrology Anupam Agarwal, MD, FASN University of Alabama at Birmingham University of Alabama at Birmingham Dynamed - my role is to review Goldilocks Therapeutics, Inc. Genzyme/Sanofi Fabry Fellowship Univ Southern California, Vanderbilt Editorial Board of AJP Renal, Kidney My wife, Lisa Curtis, will be President- content related to AKI for Dynamed Award Int and Lab Investigation. elect for Women in Nephrology (2018- and review updated materials I have been invited to serve on the 2019). prepared by the Dynamed editorial Advisory board of Goldilocks team for AKI topics. Therapeutics, a NY based company investigating delivery of drugs in the kidney using nanotechnology for acute and chronic kidney disease. Krishna A. Agarwal, MD UMMS-Baystate UMMS-Baystate Founder, MEDSICON Founder, I-MediSTAR Mariam Aghajan, PhD Ionis Pharmaceuticals Ionis Pharmaceuticals Ionis Pharmaceuticals Arash Aghajani Nargesi, MD, MPH Mayo Clinic Mayo Clinic Central Society for Clinical and Translational Research: CSCTR in the amount of $500 for an oral presentation of my research in the annual 2018 meeting Giulia Agnello, PhD Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc. Nikhil Agrawal, MD Beth Israel Deaconess Medical Beth Israel Deaconess Medical center Center Shipra Agrawal, PhD The Research Institute at Nationwide Nationwide Children's Hospital and Children's Hospital The Ohio State University Judith Agudo, PhD Dana-Farber Cancer Institute Dana-Farber Cancer Institute Timna Agur, MD Christine Ahlström, PhD AstraZeneca R&D AstraZeneca R&D Sofia B. Ahmed, MD University of Calgary University of Calgary Curie Ahn, MD, PhD Seoul National University Hospital Seoul National University Hospital Maria Ajaimy, MD Montefiore Medical Center Montefiore Medical Center Enver Akalin, MD, FASN Montefiore Medical Center Montefiore Medical Center, Albert Astellas, Caredx, Angion, NIH Einstein College of Medicine 10/17/2018 ASN Kidney Week 2018 Disclosures 2 Nothing to Full Name Organization Current Employer Consultancy Ownership Interest Research Funding Honoraria Patents and Inventions Scientific Advisor or Membership Speakers Bureau Other Interests/Relationships Disclose Kemal Marc Akat, MD, DrMed The Rockefeller University Alireza Akbari, PhD London Health Sciences Centre Western University Shreeram Akilesh, MD, PhD University of Washington University of Washington Tadao Akizawa, MD Showa University School of Medicine Showa University School of Medicine Kyowa Kirin, Bayer, Kyowa Kirin, Bayer, Ono,Torii, Bayer, Kyowa Kirin, Ono,Torii,Kissei Astellas,GlaxoSmithKline,JT, ,Fuso,Kissei,Chugai Nipro,Ono,Torii, ,Fuso,Kissei Elvis A. Akwo, MD, PhD Vanderbilt University Medical Center Vanderbilt University Medical Center Nada Alachkar, MD Johns Hopkins Hospital Up to Date Member, American Society of Transplantation Kidney Pancreas Community of Practice (KPCOP) Executive Committee Fadwa S. Al-Ali, MD Hamad Medical Corporation Ziyad Al-Aly, MD, FASN VA Saint Louis Health Care System VA Saint Louis Health Care System VA (Department of Veteran Affairs). Board of Directors, Veterans Research and Education Foundation of Saint Louis Editorial boards: JASN, CJASN, Transplant International, Translational Research, Clinical Nephrology, European Medical Journal- Nephrology. ASN Publications Committee Ahsan Alam, MD McGill University Health Centre McGill University Otsuka Canada Otsuka Canada Otsuka Canada Royal College International (Canada) Otsuka USA Otsuka USA Otsuka USA Shady Y. Albakry Weill Cornell Medical College Weill Cornell Medical College Valeria Gabriela Alberton hospital Fernandez Hospital Fernandez Imad Al-Dakkak Alexion Alexion Alexion John H. Alexander, MD Duke Clinical Research Institute Duke University AbbVie Institutional research grants from: Bristol Myers Squibb Bristol Myers Squibb CSL Behring Boehringer Ingelheim Janssen CryoLife Novo Nordisk CSL Behring Pfizer Food and Drug Administration Portola National Institutes of Health Teikoku Sanofi VA Cooperative Studies Program Tenax Therapeutics Zafgen VoluMetrix Mariam P. Alexander, MD Stephen I. Alexander, MD, MBBS, MPH Centre for Kidney Research, Centre for Kidney Research, Children?s Hospital at Westmead. Children?s Hospital at Westmead. Leonidas G. Alexopoulos, PhD National Technical Univ of Athens National Technical Univ of Athens Protavio Ltd Tarek Alhamad, MD, MS, FASN Washington University in St. Louis Mallinckrodt CareDx CareDx CareDx Veloxis Veloxis Angion Sanofi Sanofi Mohammed Farhan Ali, MD Quaisar Ali, PhD Angion Biomedica Corp. Angion Biomedica Corp. Sehrish Ali, DO BCM Nephrology BCM Nephrology Radica Z. Alicic, MD Providence Medical Research Center Providence Medical Research Center Janssen Research & Development : Providence Health Care 85,738 $ BioPorto : 36,011 $ Wynand Alkema Radboud University Medical Center Radboud University Medical Center NIZO Food Research James S. Allan, MD, MBA Massachusetts General Hospital Massachusetts General Hospital Andrew S. Allegretti, MD, MS Massachusetts General Hospital MGH Theracos, LLC Michael Allon, MD University of Alabama at Birmingham University of Alabama at Birmingham CorMedix Salem Almaani, MD, MS The Ohio State University The Ohio State University ASN NKF CSN Charles E. Alpers, MD University of Washington Medical University of Washington Abbvie; AstraZeneca; Omeros; Abbvie; Boehringer-Ingelheim Editorial Boards: CJASN Laboratory Center ChemoCentrryx; Pfizer; Achillion Investigation Human Pathology American Journal of Pathology Journal of Nephrology Current Opinion in Nephrology and Hypertension Scientific World Journal Susan E. Alters, PhD Aeglea Biotherapeutics Aeglea Biotherapeutics Aeglea Biotherapeutics Aeglea Biotherapeutics Magnus Althage, PhD AstraZeneca AstraZeneca Beth A. Altschafl, MS, PhD University of Wisconsin-Madison University of Wisconsin-Madison Jessica A. Alvarez, PhD, RD Emory University SOM Kerstin U. Amann, MD University Hospital Erlangen University Hospital Erlangen Alexion Co. Walter T. Ambrosius, PhD Wake Forest School of Medicine Wake Forest School of Medicine I serve on DSMBs for NIH-funded I receive royalties from
Recommended publications
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • 2008 June;38(2)
    9^k^c\VcY=neZgWVg^XBZY^X^cZKdajbZ(-Cd#'?jcZ'%%- EJGEDH:HD;I=:HD8>:I>:H IdegdbdiZVcY[VX^a^iViZi]ZhijYnd[VaaVheZXihd[jcYZglViZgVcY]neZgWVg^XbZY^X^cZ Idegdk^YZ^c[dgbVi^dcdcjcYZglViZgVcY]neZgWVg^XbZY^X^cZ IdejWa^h]V_djgcVaVcYidXdckZcZbZbWZghd[ZVX]HdX^ZinVccjVaanViVhX^Zci^ÄXXdc[ZgZcXZ HDJI=E68>;>8JC9:GL6I:G :JGDE:6CJC9:GL6I:G6C9 B:9>8>C:HD8>:IN 76GDB:9>86AHD8>:IN D;;>8:=DA9:GH D;;>8:=DA9:GH EgZh^YZci EgZh^YZci 9gB^`Z7ZccZii 1B#7ZccZii5jchl#ZYj#Vj3 Egd[#6a[7gjWV`` 1Va[#d#WgjWV``5cicj#cd3 EVhiçEgZh^YZci K^XZEgZh^YZci 9g8]g^h6Xdii 1XVXdii5deijhcZi#Xdb#Vj3 9gEZiZg<Zgbdceg 1eZiZg#\ZgbdcegZ5b^a#WZ3 HZXgZiVgn >bbZY^ViZEVhiEgZh^YZci 9gHVgV]AdX`aZn 1hejbhhZXgZiVgn5\bV^a#Xdb3 9gCdZb^7^iiZgbVc 1cdZb^W5im#iZX]c^dc#VX#^a3 IgZVhjgZg EVhiEgZh^YZci 9g<jnL^aa^Vbh 1hejbh5[VhibV^a#cZi3 9gGVb^gd8Va^"8dgaZd 1^gdXVa^5YVcZjgdeZ#dg\3 :YjXVi^dcD[ÄXZg =dcdgVgnHZXgZiVgn 9g9Vk^YHbVgi 1YVk^Y#hbVgi5Y]]h#iVh#\dk#Vj3 9g?dZg\HX]bjio 1_dZg\#hX]bjio5]^c#X]3 EjWa^XD[ÄXZg BZbWZgViAVg\Z'%%, 9gKVcZhhV=VaaZg 1kVcZhhV#]VaaZg5XYbX#Xdb#Vj3 9gE]^a7gnhdc 1e]^a#Wgnhdc5YYgX#dg\3 8]V^gbVc6CO=B< BZbWZgViAVg\Z'%%+ 9g9Vk^YHbVgi 1YVk^Y#hbVgi5Y]]h#iVh#\dk#Vj3 Egd[#BV^YZ8^bh^i 1bX^bh^i5^hiVcWja#ZYj#ig3 8dbb^iiZZBZbWZgh BZbWZgViAVg\Z'%%* 9g<aZc=Vl`^ch 1]Vl`ZnZ5hl^[iYha#Xdb#Vj3 9g6gb^c@ZbbZg 1Vgb^c5`ZbbZgh#YZ3 9gHVgV]H]Vg`Zn 1hVgV]#h]Vg`Zn5YZ[ZcXZ#\dk#Vj3 9gHXdiiHfj^gZh 1hXdii#hfj^gZh5YZ[ZcXZ#\dk#Vj3 69B>C>HIG6I>DC 69B>C>HIG6I>DC BZbWZgh]^e =dcdgVgnIgZVhjgZgBZbWZgh]^eHZXgZiVgn HiZkZ<dWaZ 1hejbhVYb5W^\edcY#cZi#Vj3 EVig^X^VLddY^c\ &+7jghZab6kZcjZ!=V^cVjai!>a[dgY B:B7:GH=>E :hhZm!><+(:=!Jc^iZY@^c\Ydb
    [Show full text]
  • Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm
    Velliv noterede aktier i alt pr. 30-06-2021 ISIN Udstedelsesland Navn Markedsværdi (i DKK) US0378331005 US APPLE INC 1.677.392.695 US5949181045 US MICROSOFT CORP 1.463.792.732 US0231351067 US AMAZON.COM INC 1.383.643.996 DK0060534915 DK NOVO NORDISK A/S-B 1.195.448.146 US30303M1027 US FACEBOOK INC-CLASS A 1.169.094.867 US02079K3059 US ALPHABET INC-CL A 867.740.769 DK0010274414 DK DANSKE BANK A/S 761.684.457 DK0060079531 DK DSV PANALPINA A/S 629.313.827 US02079K1079 US ALPHABET INC-CL C 589.305.120 US90138F1021 US TWILIO INC - A 514.807.852 US57636Q1040 US MASTERCARD INC - A 490.766.560 US4781601046 US JOHNSON & JOHNSON 478.682.981 US70450Y1038 US PAYPAL HOLDINGS INC 471.592.728 DK0061539921 DK VESTAS WIND SYSTEMS A/S 441.187.698 US79466L3024 US SALESFORCE.COM INC 439.114.061 US01609W1027 US ALIBABA GROUP HOLDING-SP ADR 432.325.255 US8835561023 US THERMO FISHER SCIENTIFIC INC 430.036.612 US22788C1053 US CROWDSTRIKE HOLDINGS INC - A 400.408.622 KYG875721634 HK TENCENT HOLDINGS LTD 397.054.685 KR7005930003 KR SAMSUNG ELECTRONICS CO LTD 389.413.700 DK0060094928 DK ORSTED A/S 378.578.374 ES0109067019 ES AMADEUS IT GROUP SA 375.824.429 US46625H1005 US JPMORGAN CHASE & CO 375.282.618 US67066G1040 US NVIDIA CORP 357.034.119 US17275R1023 US CISCO SYSTEMS INC 348.160.692 DK0010244508 DK AP MOLLER-MAERSK A/S-B 339.783.859 US20030N1019 US COMCAST CORP-CLASS A 337.806.502 NL0010273215 NL ASML HOLDING NV 334.040.559 CH0012032048 CH ROCHE HOLDING AG-GENUSSCHEIN 325.008.200 KYG970081173 HK WUXI BIOLOGICS CAYMAN INC 321.300.236 US4370761029 US HOME DEPOT INC 317.083.124 US58933Y1055 US MERCK & CO.
    [Show full text]
  • EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009
    December 22, 2008 EP Vantage Interview - Silence hoping to have something to shout about in 2009 Lisa Urquhart With its first product expected to go into the clinic potentially as early as January, Silence Therapeutics is hoping that 2009 will be year it has something to shout about and one that will reverse the alarming share price decline that has seen the company’s valuation slip from a high of over £170m in June 2007 to £21.6m today. Silence is one of a growing number of companies working in RNA interference (RNAi) and particularly short interfering RNA (siRNA), which work by selectively silencing or inactivating genes related to certain diseases. It is importantly one of only two companies that have composition of matter patent protection for their siRNA drugs. Speaking to EP Vantage, Iain Ross, chief executive of Silence, says: “It’s a big year coming up for us.” The group has spent most of the last 12 months strengthening its IP position, and next year comes the important move of the group’s lead candidate Atu027 into the clinic, an event Mr Ross says should take place in the first quarter of the year. Many expect it could be as soon as the end of January. Partnering focus What is less expected is the speed at which Mr Ross intends to partner the drug, which is being developed in solid tumours, with an emphasis on lung cancer. “We would be looking at doing something either at the end of 2009 or the beginning of 2010,” he says. Key to partnering discussions will be the drug demonstrating good safety data in a number of cancer patients, which could be the catalyst to starting talks with big pharma who have already started to ask about Atu027.
    [Show full text]
  • IQVIA Pharma Deals Half-Year Review of 2020
    White Paper IQVIA Pharma Deals Half-Year Review of 2020 HEATHER CARTWRIGHT, Senior Analyst, Global Market Insights, IQVIA MICHELLE LIU, Analyst, Global Market Insights, IQVIA TASKIN AHMED, Manager, Global Market Insights, IQVIA Table of contents Introduction 1 Uncertainty and prudence cause M&A to stall 2 Licensing deal values continue to rise 5 Roche pips AstraZeneca to title of most active dealmaker 10 COVID-19 pandemic drives increase in R&D collaboration 11 Infectious diseases replace oncology as top therapeutic area for dealmaking 14 Outlook for H2 2020 15 About the authors 17 Introduction COVID-19 shakes up the dealmaking landscape H1 2020 was an unprecedented time for dealmaking in the life sciences sector. While the COVID-19 pandemic rapidly provoked a significant level of partnering activity amongst biopharma companies keen to expedite the development of vaccines or therapeutics to tackle the virus, it also acted as a brake on other types of dealmaking, most notably M&A which saw a sharp decline in activity as a result of uncertainty and operational disruption. Indeed, H1 2020 was notable for the absence of any US$5 B deals on the scale seen in previous years as companies instead focused their attentions on internal programs and potential COVID-19 solutions, opting only for a few asset-driven acquisitions. There was also plentiful capital available to allow biotech companies to stay independent, particularly those in the US. As a result, aggregate spending on M&A by life science companies plummeted to just US$19.1 B in the first 6 months of 2020.
    [Show full text]
  • SCUBA Medical Statement
    MEDICAL STATEMENT Participant Record (Confidential Information) Please read carefully before signing. This is a statement in which you are informed of some potential risks established safety procedures are not followed, however, there are involved in scuba diving and of the conduct required of you during the increased risks. scuba training program. Your signature on this statement is required for To scuba dive safely, you should not be extremely overweight or you to participate in the scuba training program offered out of condition. Diving can be strenuous under certain conditions. Your respiratory and circulatory systems must be in good health. All body air by STAFF and spaces must be normal and healthy. A person with coronary disease, a Instructor current cold or congestion, epilepsy, a severe medical problem or who is under the influence of alcohol or drugs should not dive. If you have GEORGIA TECH CAMPUS RECREATION CENTER located in the asthma, heart disease, other chronic medical conditions or you are tak- Facility ing medications on a regular basis, you should consult your doctor and the instructor before participating in this program, and on a regular basis city of ATLANTA , state/province of GEORGIA . thereafter upon completion. You will also learn from the instructor the important safety rules regarding breathing and equalization while scuba Read this statement prior to signing it. You must complete this diving. Improper use of scuba equipment can result in serious injury. You Medical Statement, which includes the medical questionnaire section, to must be thoroughly instructed in its use under direct supervision of a enroll in the scuba training program.
    [Show full text]
  • Brownie's THIRD LUNG
    BrMARINEownie GROUP’s Owner’s Manual Variable Speed Hand Carry Hookah Diving System ADVENTURE IS ALWAYS ON THE LINE! VSHCDC Systems This manual is also available online 3001 NW 25th Avenue, Pompano Beach, FL 33069 USA Ph +1.954.462.5570 Fx +1.954.462.6115 www.BrowniesMarineGroup.com CONGRATULATIONS ON YOUR PURCHASE OF A BROWNIE’S SYSTEM You now have in your possession the finest, most reliable, surface supplied breathing air system available. The operation is designed with your safety and convenience in mind, and by carefully reading this brief manual you can be assured of many hours of trouble-free enjoyment. READ ALL SAFETY RULES AND OPERATING INSTRUCTIONS CONTAINED IN THIS MANUAL AND FOLLOW THEM WITH EACH USE OF THIS PRODUCT. MANUAL SAFETY NOTICES Important instructions concerning the endangerment of personnel, technical safety or operator safety will be specially emphasized in this manual by placing the information in the following types of safety notices. DANGER DANGER INDICATES AN IMMINENTLY HAZARDOUS SITUATION WHICH, IF NOT AVOIDED, WILL RESULT IN DEATH OR SERIOUS INJURY. THIS IS LIMITED TO THE MOST EXTREME SITUATIONS. WARNING WARNING INDICATES A POTENTIALLY HAZARDOUS SITUATION WHICH, IF NOT AVOIDED, COULD RESULT IN DEATH OR INJURY. CAUTION CAUTION INDICATES A POTENTIALLY HAZARDOUS SITUATION WHICH, IF NOT AVOIDED, MAY RESULT IN MINOR OR MODERATE INJURY. IT MAY ALSO BE USED TO ALERT AGAINST UNSAFE PRACTICES. NOTE NOTE ADVISE OF TECHNICAL REQUIREMENTS THAT REQUIRE PARTICULAR ATTENTION BY THE OPERATOR OR THE MAINTENANCE TECHNICIAN FOR PROPER MAINTENANCE AND UTILIZATION OF THE EQUIPMENT. REGISTER YOUR PRODUCT ONLINE Go to www.BrowniesMarineGroup.com to register your product.
    [Show full text]
  • Together As One
    March 2017 | Issue 28 1 The ESSEXCRICKETER Members’ Magazine TOGETHER AS ONE YOUR CLUB. YOUR COUNTY. YOUR PASSION. Featured Inside... Chris Silverwood | Season Preview | New Signings Tom Westley | Harry McQueen | Matt Quinn | Aaron Beard Job: 27044_WG_cricket_advert_A4_AW Proof Read by: Operator: Phil Proof: 01 Set-up: Phil Date: 2 March 2017 10:11 AM First Read/Revisions Another season WE of superb deliveries MAKE www.woodlandgroup.com EVERY [email protected] DELIVERY COUNT YOUR CLUB. YOUR COUNTY. YOUR PASSION. Photography credit: Nick Wood/Unshaken Photography 3 Contents 5 John Faragher 7 Derek Bowden 9 Chris Silverwood 11 Tendo Talks 13 Ground Improvements 15 - 17 Season Preview 19 New Signings 21 - 22 Essex Boundary Club 24 Tom Westley 26 Harry McQueen 28 - 29 Springfield Hospital 31 Matt Quinn 33 Member’s Preview 35 Klarners Coaches 37 Essex Abroad We care. We connect. We deliver. 39 Aaron Beard www.woodlandgroup.com 41 Essex County Cricket Board News 43 Fixtures 27044_WG_cricket_advert_A4_AW.indd 1 02/03/2017 10:52 Job: 27044_WG_cricket_advert_A4_AW Proof Read by: Operator: Phil Proof: 01 Set-up: Phil Date: 2 March 2017 10:11 AM First Read/Revisions 3 CONTENTS WELCOME Another season of superb deliveries elcome to the March 2017 and staff and we catch up with new magazine. These will keep you in edition of your ‘The Essex Strength and Conditioning Coach Harry the loop of various goings on WE Cricketer’ magazine. McQueen about the winter work he has around the Club as well as including WFollowing on from the successes of implemented. feature interviews with each last year, a winter of hard work has competitions star.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Reduction in the Risk of Major Adverse Cardiovascular Events
    Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial Gregory G. Schwartz1, Stephen J. Nicholls2, Henry N. Ginsberg3, Jan O. Johansson4, Kamyar Kalantar‐Zadeh5, Ewelina Kulikowski4, Peter P Toth6, Norman Wong4, Michael Sweeney4, Kausik K Ray7 On behalf of the BETonMACE Investigators 1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO USA; 2Monash University Cardiovascular Research Center, Melbourne, Australia; 3Vagelos College of Physicians and Surgeons, Columbia University, New York, NY USA; 4Resverlogix Corp., Calgary, Alberta, Canada; 5University of California Irvine School of Medicine, Orange, CA USA; 6CGH Medical Center, Sterling, IL and Johns Hopkins University, Baltimore, MD USA; 7Imperial College Center for Cardiovascular Disease Prevention, London UK American Heart Association – 2020 Scientific Sessions November 2020 ClinicalTrials.gov: NCT02586155 Disclosures • The BETonMACE trial was funded by Resverlogix • Dr Schwartz reports research grants to the University of Colorado from Resverlogix, Sanofi, The Medicines Company, and Roche; and is coinventor of pending US patent 14/657192 (“Methods of Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. • Dr. Nicholls reports grants from Resverlogix, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Guide to Theecological Systemsof Puerto Rico
    United States Department of Agriculture Guide to the Forest Service Ecological Systems International Institute of Tropical Forestry of Puerto Rico General Technical Report IITF-GTR-35 June 2009 Gary L. Miller and Ariel E. Lugo The Forest Service of the U.S. Department of Agriculture is dedicated to the principle of multiple use management of the Nation’s forest resources for sustained yields of wood, water, forage, wildlife, and recreation. Through forestry research, cooperation with the States and private forest owners, and management of the National Forests and national grasslands, it strives—as directed by Congress—to provide increasingly greater service to a growing Nation. The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, age, disability, and where applicable sex, marital status, familial status, parental status, religion, sexual orientation genetic information, political beliefs, reprisal, or because all or part of an individual’s income is derived from any public assistance program. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.) should contact USDA’s TARGET Center at (202) 720-2600 (voice and TDD).To file a complaint of discrimination, write USDA, Director, Office of Civil Rights, 1400 Independence Avenue, S.W. Washington, DC 20250-9410 or call (800) 795-3272 (voice) or (202) 720-6382 (TDD). USDA is an equal opportunity provider and employer. Authors Gary L. Miller is a professor, University of North Carolina, Environmental Studies, One University Heights, Asheville, NC 28804-3299.
    [Show full text]